ENPICOM secures extended financing from current investors

Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions

Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction

Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program

Sun Pharma presents data from Phase 1 studies of GL0034

GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity

Natural Capsules announces strategic investment by Somerset Indus Capital Partners

Max Healthcare and IIT Bombay ink MoU for innovation in the healthcare industry

Quantiphi join hands with Pharmarack and Snowflake to drive AI based innovation

This partnership will revolutionize Pharmarack's digital infrastructure with Snowflake's single, integrated platform to facilitate advanced analytic

DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine

The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield

Croda opens technical centre in Hyderabad

The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth

USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma

Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma